Skip to content
10-Q

Quarterly Report

Vir Biotechnology, Inc. VIR

0001628280-26-031471

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 29, 2026 168.65M sh
Shares Diluted Q1 2026 · Mar 31, 2026 147.36M sh
Shares Diluted Q1 2026 · Mar 31, 2025 137.47M sh
Capex Q1 2026 · Mar 31, 2026 $390K
Capex Q1 2026 · Mar 31, 2025 $1.63M
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$132.39M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$78.12M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $274.16M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $232.19M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $273.57M
Stockholders Equity Q1 2026 · Mar 31, 2026 $812.77M
Stockholders Equity Q1 2026 · Dec 31, 2025 $765.28M
Stockholders Equity Q1 2026 · Mar 31, 2025 $1.04B
Stockholders Equity Q1 2026 · Dec 31, 2024 $1.15B
Current Liabilities Q1 2026 · Mar 31, 2026 $73.56M
Current Liabilities Q1 2026 · Dec 31, 2025 $92.82M
Total Liabilities Q1 2026 · Mar 31, 2026 $212.82M
Total Liabilities Q1 2026 · Dec 31, 2025 $237.55M
Current Assets Q1 2026 · Mar 31, 2026 $522.99M
Current Assets Q1 2026 · Dec 31, 2025 $514.08M
Total Assets Q1 2026 · Mar 31, 2026 $1.03B
Total Assets Q1 2026 · Dec 31, 2025 $1B
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.85
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.88
Eps Basic Q1 2026 · Mar 31, 2026 −$0.85
Eps Basic Q1 2026 · Mar 31, 2025 −$0.88
Sga Expense Q1 2026 · Mar 31, 2026 $23.34M
Sga Expense Q1 2026 · Mar 31, 2025 $23.94M
Rd Expense Q1 2026 · Mar 31, 2026 $108.92M
Rd Expense Q1 2026 · Mar 31, 2025 $118.65M
Net Income Q1 2026 · Mar 31, 2026 −$125.7M
Net Income Q1 2026 · Mar 31, 2025 −$120.97M
Operating Income Q1 2026 · Mar 31, 2026 −$132.29M
Operating Income Q1 2026 · Mar 31, 2025 −$139.55M